Showing results (1821-1830 of 1,877) with videos related to

Sort By:
Pageof 188
Leukemia|November 21, 2013
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)E M Ocio, P G Richardson, S V Rajkumar, et al.
European Journal of Neurology|April 18, 2020
Advanced multiparametric magnetic resonance imaging of multinodular and vacuolating neuronal tumorA Lecler, V Broquet, J Bailleux, et al.
Blood Cancer Journal|October 24, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Cyrille Hulin, Alexis Talbot, et al.
The Lancet. Oncology|October 2, 2025
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trialSalomon Manier, Jérôme Lambert, Cyrille Hulin, et al.
European Journal of Human Genetics : EJHG|November 30, 2021
A polygenic risk score for multiple myeloma risk predictionFederico Canzian, Chiara Piredda, Angelica Macauda, et al.
Leukemia|July 4, 2018
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisBrian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Leukemia|December 24, 2011
Management of treatment-emergent peripheral neuropathy in multiple myelomaP G Richardson, M Delforge, M Beksac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future ApplicationsKenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2022
Molecular and clinical diversity in primary central nervous system lymphomaI Hernández-Verdin, E Kirasic, K Wienand, et al.
The Lancet. Oncology|August 12, 2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaShaji Kumar, Bruno Paiva, Kenneth C Anderson, et al.
Pageof 188